Hazel Aleen Marcum passed away peacefully on August 24, 2025, in Grove City, Ohio, at the age of 82. Born on November 17, 1942, in Louisa, Kentucky, Hazel lived a life marked by devotion to her family ...

What does this Advisor Specialize in? Find a financial advisor who specializes in the area of expertise you require. It's important to find an advisor who can help you approach your personal and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. This activity is supported by independent medical ...

Please provide your email address to receive an email when new articles are posted on . “This is a really exciting new mechanism of action for our field, hoping to improve functional as well as ...

Donald Harris Carrico was called to a higher place on August 22, 2025 at the age of 77, surrounded by his family and under the loving care of his wife of 50 years, Joann. Donnie was born on November ...

Despite a confident start, a target of 293 proved too much for the hosts, as England dramatically collapsed from 132 for two to 205 all out. Bangladesh's spinners combined to take eight wickets.

The Central Depository Company of Pakistan (CDC) has onboarded AKD Securities Limited to its RAAST Aggregator Platform, enabling investors to transfer funds instantly and securely. This strategic ...

New seven-year data from the LADDER study show Contivue with Susvimo provides good visual outcomes with stable retinal anatomy over the longer term 2 With up to two refills per year, Contivue with ...

Susvimo is under review with the EMA and once approved will be the first continuous delivery treatment for nAMD, affecting 1,7 million in the European Union1 New seven-year data from the LADDER study ...

In AVONELLE-X, the largest long-term extension trial in nAMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end1 Over 60% of ...

Belgian biotech Oxurion has revealed new data from a phase 2 trial of its plasma kallikrein inhibitor THR-149, in development for people with diabetic macular oedema (DME) who don't respond to ...